1-Ackermann E and Brill A .(1974). “Xanthin oxidase activity in method of enzymatic analysis” ed. Bergmeyer H.U., 2nd ed.,Academic press Inc. U.S.A, 521-522.
2-DavidE.metzler.(2004). “Biochemistry the chemical reaction of living cells” volums 1and 2 second edition , 16: 890-891 .
3- Wolthers K and Schimerlik M. (2001). “Biochemistry”, 40: 4722 – 4737.
4 – Robert K. Daryl K. Peter A. and Victor W.(2006). “ Harper’s Illustrated Biochemistry” , twenty-sixth edition ,49:571-572.
5- Chan N. Rogers P and Arnone A. (1998). “Biochemistry “, 37: 1459 – 1464
6-Schelvis, J. P. M., Zhao, Y, Marletta, M. A and Babcock, G. (1998) “Biochemistry”, 37:16289 – 16297.
7-Roberts S. Weichsel A. Qiu Y. Shelnutt J. Walker F. and Montfort, W. (2001).”Biochemistry” 40: 1327 – 1337.
8- Jeremy M.John L.Lubert Stryer. (2003). “Biochemistry fifth edition”, 49:686-687.
9- Ghosh, D. K., and Stuehr, D. J. (1995) “Biochemistry”, 34, 801 – 807
10-Ackermann E and Brill A.(1974). “Xanthin oxidase activity In method of enzymatic analysis” ed. Bergmeyer H.U.2nd ed., academic press inc., USA, 512-522.
11-Vanuffelen B.E., Van Derzec J. and DekosterB.M.(1998).Biochem.J., 330,719 ,cited by Al-Zamely et al (2001).
12-Friedewald W. Levy R and Fredrictson D.(1972). “Estimation of low density lipoprotein cholesterol in plasma without use of the preparative ultra centrifuge” .Clin.Chem, 18(6):499-502.
13. Shishehbor M .Aviles R and Brennan M.(2003). “Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy”. JAMA; 289:1675–1680.
14. Shishehbor M. Brennan M and Aviles RJ. (2003). “Statins promote potent systemic antioxidant effects through specific inflammatory pathways”. Circulation; 108:426–431.
15-katzung B.nitric oxide ,Donors and inhibitors . in :Basic and Clinical pharmacology. 8th ed., Lange medical books /Mc graw-Hill Medical publishing Division , New Yourk , PP. 326–332.
16-NCEP: The National Cholesterol Education program Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Third report ( adult treatment panel III). JAMA 2004; 585: 2486- 2497.
17-Keilani T. Schlueter W and Battle D. (1995). “Selected aspects of ACE inhibitor therapy for patients with renal disease impact on proteinuria, lipids and potassium”. J. Clin. Phramacol.; 35(1): 87- 97.
18-Krentz Z. (1996). “Insulin resistance”. B. M. J. 313 (30): 1385- 1389.
19-Stensvold I. tverdal A. Urdal P and Graff leversen S.(1993). “Non fasting serum triglycerides concentration and mortality from coronary heart disease and cuase in middle aged Norwegian women”. B. M. J. 307(20): 1318- 1322.
20-Grundy S . (1997). “Small LDL, atherogenic dyslipidemia and the metabolic syndrome (editorial; comment)”. Circulation; 95: 1-4.
21-Baghdad J . Albers J . (1977). “Plasma high- density lipoprotein concentrations in chronic hemodialysis and renal disease patients”. N. Eng. J. Med.; 296: 1436- 1439.
22-Deckelbaum R . Granot E and Oscry Y.(1994). “Plasma TG determines strudture- composition in low- and high density lipoproteins. Arteriosclerosis”. 4: 225- 231.
23-Karpati I. Paragh G and Kovacs E. (1999). “Disturbed LDL and scavenger receptor functions in monocytes from chronic hemodialysed patients”. Nephrol. Dial. Transplant.; 14: 2664- 2668.
24-Akira K. Yoshinori M. Isao O and Kazuki N. (2001).“relationship between triglycerides concentration and LDL size evaluated by malondialdehyde modified LDL”. Clinical chemistry, 479(5): 893- 900.